Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer

Mutations in the estrogen receptor (ESR1) gene are common in ER-positive breast cancer patients who progress on endocrine therapies. Most mutations localise to just three residues at, or near, the C-terminal helix 12 of the hormone binding domain, at leucine-536, tyrosine-537 and aspartate-538. To i...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrod, Alison, Lai, Chun-Fui, Goldsbrough, Isabella, Simmons, Georgia M., Oppermans, Natasha, Santos, Daniela B., Győrffy, Balazs, Allsopp, Rebecca C., Toghill, Bradley J., Balachandran, Kirsty, Lawson, Mandy, Morrow, Christopher J., Surakala, Manasa, Carnevalli, Larissa S., Zhang, Pei, Guttery, David S., Shaw, Jacqueline A., Coombes, R. Charles, Buluwela, Lakjaya, Ali, Simak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613769/
https://www.ncbi.nlm.nih.gov/pubmed/36198774
http://dx.doi.org/10.1038/s41388-022-02483-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613769/
https://www.ncbi.nlm.nih.gov/pubmed/36198774
http://dx.doi.org/10.1038/s41388-022-02483-8

Ejemplares similares